
FDA Issues Complete Response Letter to Aldeyra for Reproxalap Dry Eye NDA
FDA Issues Complete Response Letter to Aldeyra for Reproxalap Dry Eye NDA Aldeyra Therapeutics, Inc.a biotechnology company committed to the development of innovative therapies targeting immune-mediated and metabolic diseases, announced…











